{
  "ticker": "ALNY",
  "company_name": "Alnylam Pharmaceuticals",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT01148953",
      "title": "Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Transthyretin Mediated Amyloidosis (ATTR)",
      "start_date": "2010-06",
      "completion_date": "2012-02",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT03774784",
      "title": "A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis",
      "start_date": "2019-01-29",
      "completion_date": "2020-05-18",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT06659640",
      "title": "A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Hereditary Hemorrhagic Telangiectasia",
      "start_date": "2024-11-11",
      "completion_date": "2028-06-22",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT03767829",
      "title": "A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease",
      "start_date": "2018-12-05",
      "completion_date": "2020-06-25",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT04883905",
      "title": "ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Acute Hepatic Porphyria",
      "start_date": "2021-04-26",
      "completion_date": "2027-04-01",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT05661916",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Transthyretin-Mediated Amyloidosis",
      "start_date": "2023-01-16",
      "completion_date": "2025-09-30",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT06679946",
      "title": "A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "PHASE3",
      "condition": "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
      "start_date": "2024-12-03",
      "completion_date": "2028-05-30",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT01617967",
      "title": "Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "TTR-mediated Amyloidosis",
      "start_date": "2012-05",
      "completion_date": "2014-01",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT00496821",
      "title": "Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Respiratory Syncytial Virus Infections",
      "start_date": "2007-07",
      "completion_date": "2007-11",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT06393712",
      "title": "A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Cerebral Amyloid Angiopathy",
      "start_date": "2024-05-17",
      "completion_date": "2029-11-01",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 15,
      "": 9,
      "PHASE1, PHASE2": 5,
      "PHASE3": 5,
      "PHASE2": 13,
      "EARLY_PHASE1": 2,
      "NA": 1
    },
    "by_status": {
      "COMPLETED": 28,
      "TERMINATED": 5,
      "RECRUITING": 10,
      "ENROLLING_BY_INVITATION": 1,
      "APPROVED_FOR_MARKETING": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "NO_LONGER_AVAILABLE": 1,
      "NOT_YET_RECRUITING": 1,
      "WITHDRAWN": 1
    },
    "active_trials": 12,
    "completed_trials": 28,
    "conditions": [
      "Acute Hepatic Porphyria",
      "Acute Intermittent Porphyria",
      "Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP), Porphyria, Acute Intermittent, Acute Porphyria",
      "Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma",
      "Alzheimer's Disease",
      "Amyloidosis, Hereditary, Transthyretin Amyloidosis",
      "Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis",
      "Antitrypsin Deficiency Liver Disease",
      "Cerebral Amyloid Angiopathy",
      "Chronic Hepatitis B",
      "Early-Onset Alzheimer Disease",
      "Familial Amyloidotic Cardiomyopathy (FAC)",
      "Healthy",
      "Healthy Volunteers",
      "Hepatitis B, Chronic",
      "Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection, HBV",
      "Hereditary Hemorrhagic Telangiectasia",
      "Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy",
      "Hypertension",
      "IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA",
      "PH1, Primary Hyperoxaluria, RNAi Therapeutic, siRNA, AGT",
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis",
      "Primary Hyperoxaluria",
      "Primary Hyperoxaluria Type 1 (PH1)",
      "Primary Hyperoxaluria Type 1, Primary Hyperoxaluria",
      "Respiratory Syncytial Virus Infections",
      "Solid Tumors",
      "TTR-mediated Amyloidosis",
      "TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related",
      "Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP), ATTR Amyloidosis, Familial Amyloid Neuropathies",
      "Transthyretin Amyloidosis",
      "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
      "Transthyretin Amyloidosis With Cardiomyopathy",
      "Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis",
      "Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies",
      "Transthyretin Mediated Amyloidosis (ATTR)",
      "Transthyretin-Mediated Amyloidosis",
      "Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis",
      "Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)",
      "Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy",
      "ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:25.096943",
    "search_query": "Alnylam Pharmaceuticals",
    "url": "https://clinicaltrials.gov/search?term=Alnylam+Pharmaceuticals"
  }
}